跳转至内容
Merck
所有图片(1)

文件

33999

Supelco

利福昔明

VETRANAL®, analytical standard

别名:

4-脱氧-4′-甲基吡啶并[1′,2′-1,2]咪唑并[5,4-c]利福霉素 SV, 利福昔明

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C43H51N3O11
CAS号:
80621-81-4
分子量:
785.88
MDL號碼:
MFCD00864973
分類程式碼代碼:
41116107
PubChem物質ID:
329754738
NACRES:
NA.24

等級

analytical standard

品質等級

100

產品線

VETRANAL®

儲存期限

limited shelf life, expiry date on the label

技術

HPLC: suitable
gas chromatography (GC): suitable

應用

forensics and toxicology
pharmaceutical (small molecule)

格式

neat

SMILES 字串

CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c5c(nc6cc(C)ccn56)c4c3C2=O

InChI

1S/C43H51N3O11/c1-19-14-16-46-27(18-19)44-32-29-30-37(49)25(7)39-31(29)40(51)43(8,57-39)56-17-15-26(54-9)22(4)28(42(53)55-10)23(5)36(48)24(6)35(47)20(2)12-11-13-21(3)41(52)45-33(34(32)46)38(30)50/h11-18,20,22-24,26,28,35-36,47-50H,1-10H3,(H,45,52)/b12-11+,17-15+,21-13-/t20-,22+,23-,24-,26+,28+,35-,36-,43+/m1/s1

InChI 密鑰

HIYLTQREEOINNF-HTEWPBCCSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

Chemical structure: macrolide

應用

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

法律資訊

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

個人防護裝備

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number
BCCD4030
BCBT5109
SZBD086XV
SZBB035XV
SZB9022XV

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Gilbert G G Donders et al.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 120(2), 131-136 (2013-01-01)
To compare efficacy and tolerability between different regimens of rifaximin vaginal tablets and a placebo for treatment of bacterial vaginosis. In a prospective study carried out at 13 sites in 3 European countries between August 2009 and October 2010, White
Guy W Neff et al.
Journal of clinical gastroenterology, 47(2), 188-192 (2013-01-15)
The purpose of this study was to assess the incidence of Clostridium difficile infection in patients who received rifaximin for the treatment of hepatic encephalopathy (HE). Medical charts of patients who received rifaximin for the treatment of HE were reviewed.
Muna Qayed et al.
Journal of pediatric hematology/oncology, 35(4), e149-e152 (2013-01-01)
In murine allogeneic hematopoietic cell transplantation models, inhibiting bacterial translocation stemming from conditioning-induced damage to the gut mucosa abrogates inflammatory stimulation of donor T cells, preventing acute graft-versus-host disease (AGVHD). We conducted a phase I trial to begin testing the
Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin.
Leonard B Weinstock et al.
Journal of the American Academy of Dermatology, 68(5), 875-876 (2013-04-23)
E Mattila et al.
Alimentary pharmacology & therapeutics, 37(1), 122-128 (2012-10-26)
Clostridium difficile can cause severe antibiotic-associated colitis. Conventional treatments with metronidazole and vancomycin improve symptoms, but after discontinuation of treatment, C. difficile infection (CDI) recurs in a number of patients. Rifaximin is a rifamycin-based non-systemic antibiotic that has effect against
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门